Skip to main content
GPCR
NASDAQ Life Sciences

Structure Therapeutics' Oral Obesity Drug Aleniglipron Shows Up To 16.2% Weight Loss in Phase 2B, Phase 3 to Start Q3

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$38
Mkt Cap
$2.776B
52W Low
$15.8
52W High
$94.9
52W Position info
141% above low
Off High info
60% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

GPCR has more than doubled off its 52-week low of $15.8.

Summary

Structure Therapeutics' oral obesity drug, aleniglipron, demonstrated up to 16.2% weight loss beyond 36 weeks in its Phase 2b trial. This update provides specific, strong efficacy data following the initial positive mid-stage results announced in March and referenced in the Q1 10-Q. The drug also showed favorable tolerability with a 10.4% discontinuation rate, which is crucial for patient compliance in long-term treatments. The company plans to initiate the Phase 3 program for aleniglipron in Q3 2026.

At the time of this announcement, GPCR was trading at $38.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $15.80 to $94.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GPCR - Latest Insights

GPCR
Nov 11, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $20.95
Real-time Price: $17.53 info
Change: -$3.42 (-16%) info
Market Cap: $1.239B info
GPCR
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $17.53 info
Change: -$3.88 (-18%) info
Market Cap: $1.239B info
GPCR
Nov 09, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $17.53 info
Change: -$3.88 (-18%) info
Market Cap: $1.239B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $17.53 info
Change: -$19.25 (-52%) info
Market Cap: $1.239B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $17.53 info
Change: -$30.07 (-63%) info
Market Cap: $1.239B info